Abivax is the French biopharma built around one molecule, obefazimod, an oral small molecule that increases expression of the anti-inflammatory micro-RNA miR-124 - a mechanism the company positions as first-in-class against the cytokine-targeting biologics and JAK inhibitors that dominate ulcerative colitis. For years the investment case was a single unanswered question: does the drug actually work at the scale a registration program demands? This quarter supplied the answer. In June, the two-part readout of the phase 3 ABTECT maintenance program met its regulatory primary endpoint - placebo-adjusted clinical remission at week 44 with both doses, at p-values below 0.0001 - and then, within weeks, the company turned success into runway, raising roughly $760 million by selling 6.4 million ADSs at $125.00 each.
The sequence matters more than either event alone. The data said the drug works; the raise said management is now confident enough to fund a UC launch and a pipeline beyond it. But the same trick of timing cuts both ways. The stock closed its offering-period trading around $126.81, barely above the $125 the underwriters paid, and the market has already valued Abivax at roughly $11 billion - for a company that reported $55.7 million (EUR 48.5 million) of net loss in the first quarter of 2026, booked essentially no product revenue, and is betting a crowded, fast-moving ulcerative colitis market will adopt a novel oral mechanism against established incumbents. The quarter de-risked the binary. It did not de-risk the price. Abivax has gone from a data bet to a commercial bet, and that is a different kind of test.